CRA was hired by a biotech company with a new product in development for oncology. The main objective was to quantitatively understand current treatment dynamics and future market opportunity. We evaluated multiple data sources and developed patient flow and market map for two tumor types, using a patient-level claim data. We further created competitive landscape assessment and identified target intervention points for each scenario, in collaboration with the client. Research was conducted for both US and EU5 to size the global commercial opportunity.
Treatment patterns in patients with uterine fibroids with and without a diagnosis of heavy menstrual bleeding: Results from a large US claims database
Uterine fibroids (UF) are the most common benign pelvic tumors among women in the United States.1,2 The prevalence of UF increases with age until menopause,...